that minimize undue negative impacts of customer and sequence screening on the synthetic biology industry and the life sciences research community. The following questions are meant to elicit insights into how these responsibilities may have impacted synthetic dsDNA providers and customers.

Does implementation of the current Guidance unduly burden providers of synthetic dsDNA? If so, how could it be modified without compromising effectiveness?

Have customers experienced delays in receiving orders of synthetic dsDNA due to screening?

Have there been any undue burdens, financial, logistical, or otherwise since implementing the Guidance? If so, has it increased, especially as other costs associated with dsDNA synthesis have decreased?

What challenges, if any, do the recommendation to retain records of customer orders, "hits," and/or followup screening for at least eight years present for your organization?

How might potential changes to the Guidance to expand the scope or methodologies affect the burden for providers of dsDNA and customers (including delays to scientific progress caused by extended review)?

Is your organization concerned about legal liability challenges between customers and providers?

# **Technologies Subject to the Guidance**

The Guidance currently addresses only synthetic dsDNA and it was developed based on providers' existing protocols and technologies at that time. The life sciences field is rapidly advancing through improved bioinformatics tools, new technologies, and new discoveries. The following questions pertain to how the Guidance could be modified to address the new biosecurity risks that may be posed by advances in the life sciences.

Do other oligonucleotide types and other synthetic biological technologies, currently not covered by the Guidance, pose similar biosecurity risks as synthetic dsDNA (*e.g.*, Ribonucleic Acid [RNA], single-stranded DNA, or other oligonucleotides)?

Are there other appropriate security measures that should be established to address the potential threats arising from the use of nucleic acid synthesis, given new and emerging technologies in the life sciences?

Are there new biosecurity risks posed by the introduction of new generations of benchtop DNA synthesizers capable of synthesizing and assembling dsDNA, RNA, single-stranded DNA, or oligonucleotides in-house that should be addressed by the Guidance?

As synthetic biology becomes an increasingly digital enterprise with large databases, digital tools, robotics, and artificial intelligence, what new risks are presented to providers and consumers of synthetic oligonucleotides?

If new risks are evident, how should these risks be addressed, keeping in mind the potential impacts on providers, customers, and scientific progress?

# **Additional Considerations**

The U.S. Government is committed to mitigating the potential biosecurity risks associated with synthetic DNA and its applications, while minimizing undue impacts on providers, customers, and scientific progress.

Are there other mechanisms that the U.S. Government should consider for screening sequences, customers, or enduses that may help mitigate the biosecurity risks associated with synthetic nucleotides and their applications, while minimizing undue impacts on providers, customers, and scientific progress?

**Authority:** Section 301 of the Public Health Service Act, 42 U.S.C. 241; Section 605 of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, Pub. L. 116–22.

Dated: October 28, 2020.

#### Robert P. Kadlec,

Assistant Secretary for Preparedness and Response.

[FR Doc. 2020–24265 Filed 11–2–20; 8:45 am] BILLING CODE 4150–37–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

# Center For Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Lung Diseases.

Date: November 24-25, 2020.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting).

Contact Person: George M. Barnas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4220, MSC 7818, Bethesda, MD 20892, (301) 435– 0696, barnasg@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Member Conflict: Vascular Pathobiology.

*Date:* November 30–December 1, 2020. *Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Ai-Ping Zou, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD 20892, (301) 408– 9497, zouai@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Review of R21 Applications: RFA–OD–19–021.

*Date:* November 30, 2020.

*Time:* 2:30 p.m. to 4:30 p.m. *Agenda:* To review and evaluate grant

applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Atul Sahai, Ph.D., Scientific Review, Officer Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, (301) 435– 1198, sahaia@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Member Conflict: Cancer Biology.

*Date:* November 30, 2020.

*Time:* 12:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Rolf Jakobi, Ph.D., Scientific Review, Officer Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, (301) 495– 1718, *jakobir@mail.nih.gov.* 

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: October 28, 2020. **Miguelina Perez,**  *Program Analyst, Office of Federal Advisory Committee Policy.* [FR Doc. 2020–24306 Filed 11–2–20; 8:45 am] **BILLING CODE 4140–01–P** 

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

# Center For Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, November 19, 2020, 1 p.m. to November 19, 2020, 5 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on October 22, 2020, 85 FR 67361.

This notice is being amended to change the panel name from Aspects of Development and Disease in the Cornea to Member Conflict: Neuropsychiatric Disorders. The meeting is closed to the public.

Dated: October 28, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–24256 Filed 11–2–20; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

# Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Instrumentation and Systems Development.

*Date:* November 19, 2020.

Time: 11:00 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Kee Forbes, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5148, MSC 7806, Bethesda, MD 20892, 301–272– 4865, kee.forbes@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 19– 294: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK.

*Date:* December 1–2, 2020.

*Time:* 10:00 a.m. to 4:00 p.m. *Agenda:* To review and evaluate grant applications.

<sup>1</sup>*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451–6319, rojasr@ mail.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Sleep, Stress, Olfactory and Spatial Processing.

*Date:* December 1, 2020.

*Time:* 12:01 p.m. to 4:30 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Janita N. Turchi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5185, Bethesda, MD 20892, (301) 402–4005, turchij@mail.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Research Related to Coronavirus Disease 2019 (COVID–19).

Date: December 2, 2020.

*Time:* 9:00 a.m. to 7:00 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Baishali Maskeri, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2022, Bethesda, MD 20892, 301–827–2864, maskerib@mail.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR20–103: Collaborative Program Grant for Multidisciplinary Teams (RM1).

Date: December 2, 2020.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: William A. Greenberg, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4168, MSC 7806, Bethesda, MD 20892, (301) 435– 1726, greenbergwa@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Pathogenic Eukaryotes.

Date: December 2, 2020.

*Time:* 10:30 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tera Bounds, Ph.D., DVM, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3198, MSC 7808, Bethesda, MD 20892, (301) 435– 2306, boundst@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Neurobiology of Glia.

Date: December 2, 2020.

*Time:* 1:00 p.m. to 5:00 p.m. *Agenda:* To review and evaluate grant

applications. *Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive,

Bethesda, MD 20892 (Virtual Meeting). *Contact Person:* Peter B. Guthrie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142, MSC 7850, Bethesda, MD 20892, (301) 435– 1239, guthriep@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 29, 2020.

#### Patricia B. Hansberger,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–24368 Filed 11–2–20; 8:45 am] BILLING CODE 4140–01–P

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# **National Institutes of Health**

## Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning